Q2 2015 13F Holders as of 30 Jun 2015
-
Type / Class
-
Debt / NOTE 4.500% 7/1
-
Market price (% of par)
-
209.67%
-
Total 13F principal
-
$113,394,000
-
Principal change
-
-$3,531,000
-
Total reported market value
-
$238,347,000
-
Number of holders
-
16
-
Value change
-
-$7,108,800
-
Number of buys
-
5
-
Number of sells
-
8
Institutional Holders of MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 as of Q2 2015
As of 30 Jun 2015,
MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 was held by
16 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$113,394,000
in principal (par value) of the bond.
The largest 10 bondholders included
Citadel Advisors LLC, SILVERBACK ASSET MANAGEMENT LLC, Polygon Management Ltd., WOLVERINE ASSET MANAGEMENT LLC, ARISTEIA CAPITAL LLC, LAZARD ASSET MANAGEMENT LLC, Ameriprise Financial Inc, TANG CAPITAL MANAGEMENT LLC, JPMORGAN CHASE & CO, and Polar Capital LLP.
This page lists
16
institutional bondholders reporting positions
for the Q2 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.